Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and
blood pressure in salt-sensitive Asian hypertensive patients.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan